Provectus Biopharmaceuticals Inc (PVCT)

[vorlon1966]

In a very strange way I think the refusal benefits everything in the long run. They are now required to do another study which I hope requires them to treat every lesion as many times as they like.....with results like Moffitt's. So Moffitt's data at ASCO will be something to look at. If it matches Moffitt's data then there is proof needed for our buyout money we wanted. I don't think it will be a PIII because the letter acknowledges that all that was wrong was the missing data for symptom endpoint....pain, bleeding, infection....for that type of BTD. They have to prove it's better than standard care, so for symptom based endpoints you are going to need all symptom data. Some communication with the FDA in the next week might shed more light.

This is just my opinion.